Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03085056 · ClinicalTrials.gov registry record · Early Phase 1
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
A Early Phase 1 study of Anaplastic Thyroid Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 13
- Enrollment target
- 7
- Study locations
NCT03085056 is a Early Phase 1 study of Anaplastic Thyroid Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 13 participants, below the 26-participant average among 5 other Anaplastic Thyroid Cancer trials with a reported enrollment target (50% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT03085056, a Early Phase 1 study of Anaplastic Thyroid Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 13 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test the safety and tolerability of this treatment combination of paclitaxel and trametinib. Additionally, this study aims to to find out what effects the combination of paclitaxel and trametinib has on the shrinkage and growth of anaplastic thyroid cancer.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG Trametinib
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2026-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03085056
The ClinicalTrials.gov registry entry for NCT03085056 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26-participant average among 5 other Anaplastic Thyroid Cancer trials with a reported enrollment target (50% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anaplastic Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT03085056 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03085056 about?
NCT03085056 is a clinical study titled "Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer". The purpose of this study is to test the safety and tolerability of this treatment combination of paclitaxel and trametinib. Additionally, this study aims to to find out what effects the combination of paclitaxel and trametinib has on the shrinkage and growth of anaplastic thyroid cancer.
What is the current status of trial NCT03085056?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 13 participants. The study started on 2017-03-15. Estimated completion is 2026-09.
What conditions does trial NCT03085056 study?
This clinical trial studies the following conditions: Anaplastic Thyroid Cancer.
What interventions are being tested in trial NCT03085056?
The interventions under investigation include: Paclitaxel (DRUG), Trametinib (DRUG).
Who is sponsoring clinical trial NCT03085056?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03085056 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anaplastic Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
RECRUITING · Phase 1
-
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
COMPLETED · Phase 1
-
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.